Cargando…
Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy
Background: Fabry disease (FD) is characterized by early development of vasculopathy and endothelial dysfunction. However, it is unclear whether these findings also play a pivotal role in cardiac manifestation. As Fabry cardiomyopathy (FC) is the leading cause of death in FD, we aimed to gather a be...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104487/ https://www.ncbi.nlm.nih.gov/pubmed/30159316 http://dx.doi.org/10.3389/fcvm.2018.00108 |
_version_ | 1783349498171359232 |
---|---|
author | Loso, Jefferson Lund, Natalie Avanesov, Maxim Muschol, Nicole Lezius, Susanne Cordts, Kathrin Schwedhelm, Edzard Patten, Monica |
author_facet | Loso, Jefferson Lund, Natalie Avanesov, Maxim Muschol, Nicole Lezius, Susanne Cordts, Kathrin Schwedhelm, Edzard Patten, Monica |
author_sort | Loso, Jefferson |
collection | PubMed |
description | Background: Fabry disease (FD) is characterized by early development of vasculopathy and endothelial dysfunction. However, it is unclear whether these findings also play a pivotal role in cardiac manifestation. As Fabry cardiomyopathy (FC) is the leading cause of death in FD, we aimed to gather a better insight in pathological mechanisms of the disease. Methods: Serum samples were obtained from 17 healthy controls, 15 FD patients with and 7 without FC. FC was defined by LV wall thickening of >12 mm in cardiac magnetic resonance imaging and serum level of proBNP, high sensitive Troponin T (hsT), and globotriaosylsphingosine (lyso-GB3) were obtained. A multiplex ELISA-Assay for 23 different angiogenesis markers was performed in pooled samples. Markers showing significant differences among groups were further analyzed in single samples using specific Elisa antibody assays. L-homoarginine (hArg), L-arginine, asymmetric (ADMA), and symmetric Dimethylarginine (SDMA) were quantified by liquid chromatography—mass spectrometry. Results: Angiostatin and matrix metalloproteinase 9 (MMP-9) were elevated in FD patients compared to controls independently of the presence of FC (angiostatin: 98 ± 25 vs. 75 ± 15 ng/mL; p = 0.001; MMP-9: 8.0 ± 3.4 vs. 5.0 ± 2.4 μg/mL; p = 0.002). SDMA concentrations were highest in patients with FC (0.90 ± 0.64 μmol/l) compared to patients without (0.57 ± 0.10 μmol/l; p = 0.027) and vs. controls (0.58 ± 0.12 μmol/l; p = 0.006) and was positively correlated with indexed LV-mass (r = 0.61; p = 0.003), hsT (r = 0.56, p = 0.008), and lyso-Gb3 (r = 0.53, p = 0.013). Accordingly, the ratio of L-homoarginine to SDMA (hArg/SDMA) was lowest in patients with FC (2.63 ± 1.78) compared to controls (4.16 ± 1.44; p = 0.005). For L-arginine, hArg and ADMA no significant differences among groups could be detected, although a trend toward higher ADMA and lower hArg levels could be observed in the FC group. Furthermore, a significant relationship between kidney and cardiac function could be revealed (p = 0.045). Conclusion: Elevated MMP-9 and angiostatin levels suggest an increased extracellular matrix turnover in FD patients. Furthermore, endothelial dysfunction may also be involved in FC, as SDMA and hArg/SDMA are altered in these patients. |
format | Online Article Text |
id | pubmed-6104487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61044872018-08-29 Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy Loso, Jefferson Lund, Natalie Avanesov, Maxim Muschol, Nicole Lezius, Susanne Cordts, Kathrin Schwedhelm, Edzard Patten, Monica Front Cardiovasc Med Cardiovascular Medicine Background: Fabry disease (FD) is characterized by early development of vasculopathy and endothelial dysfunction. However, it is unclear whether these findings also play a pivotal role in cardiac manifestation. As Fabry cardiomyopathy (FC) is the leading cause of death in FD, we aimed to gather a better insight in pathological mechanisms of the disease. Methods: Serum samples were obtained from 17 healthy controls, 15 FD patients with and 7 without FC. FC was defined by LV wall thickening of >12 mm in cardiac magnetic resonance imaging and serum level of proBNP, high sensitive Troponin T (hsT), and globotriaosylsphingosine (lyso-GB3) were obtained. A multiplex ELISA-Assay for 23 different angiogenesis markers was performed in pooled samples. Markers showing significant differences among groups were further analyzed in single samples using specific Elisa antibody assays. L-homoarginine (hArg), L-arginine, asymmetric (ADMA), and symmetric Dimethylarginine (SDMA) were quantified by liquid chromatography—mass spectrometry. Results: Angiostatin and matrix metalloproteinase 9 (MMP-9) were elevated in FD patients compared to controls independently of the presence of FC (angiostatin: 98 ± 25 vs. 75 ± 15 ng/mL; p = 0.001; MMP-9: 8.0 ± 3.4 vs. 5.0 ± 2.4 μg/mL; p = 0.002). SDMA concentrations were highest in patients with FC (0.90 ± 0.64 μmol/l) compared to patients without (0.57 ± 0.10 μmol/l; p = 0.027) and vs. controls (0.58 ± 0.12 μmol/l; p = 0.006) and was positively correlated with indexed LV-mass (r = 0.61; p = 0.003), hsT (r = 0.56, p = 0.008), and lyso-Gb3 (r = 0.53, p = 0.013). Accordingly, the ratio of L-homoarginine to SDMA (hArg/SDMA) was lowest in patients with FC (2.63 ± 1.78) compared to controls (4.16 ± 1.44; p = 0.005). For L-arginine, hArg and ADMA no significant differences among groups could be detected, although a trend toward higher ADMA and lower hArg levels could be observed in the FC group. Furthermore, a significant relationship between kidney and cardiac function could be revealed (p = 0.045). Conclusion: Elevated MMP-9 and angiostatin levels suggest an increased extracellular matrix turnover in FD patients. Furthermore, endothelial dysfunction may also be involved in FC, as SDMA and hArg/SDMA are altered in these patients. Frontiers Media S.A. 2018-08-15 /pmc/articles/PMC6104487/ /pubmed/30159316 http://dx.doi.org/10.3389/fcvm.2018.00108 Text en Copyright © 2018 Loso, Lund, Avanesov, Muschol, Lezius, Cordts, Schwedhelm and Patten. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Loso, Jefferson Lund, Natalie Avanesov, Maxim Muschol, Nicole Lezius, Susanne Cordts, Kathrin Schwedhelm, Edzard Patten, Monica Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy |
title | Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy |
title_full | Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy |
title_fullStr | Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy |
title_full_unstemmed | Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy |
title_short | Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy |
title_sort | serum biomarkers of endothelial dysfunction in fabry associated cardiomyopathy |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104487/ https://www.ncbi.nlm.nih.gov/pubmed/30159316 http://dx.doi.org/10.3389/fcvm.2018.00108 |
work_keys_str_mv | AT losojefferson serumbiomarkersofendothelialdysfunctioninfabryassociatedcardiomyopathy AT lundnatalie serumbiomarkersofendothelialdysfunctioninfabryassociatedcardiomyopathy AT avanesovmaxim serumbiomarkersofendothelialdysfunctioninfabryassociatedcardiomyopathy AT muscholnicole serumbiomarkersofendothelialdysfunctioninfabryassociatedcardiomyopathy AT leziussusanne serumbiomarkersofendothelialdysfunctioninfabryassociatedcardiomyopathy AT cordtskathrin serumbiomarkersofendothelialdysfunctioninfabryassociatedcardiomyopathy AT schwedhelmedzard serumbiomarkersofendothelialdysfunctioninfabryassociatedcardiomyopathy AT pattenmonica serumbiomarkersofendothelialdysfunctioninfabryassociatedcardiomyopathy |